Vaborbactam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vaborbactam: From Antibacterial Adjuvant (β-lactamase Inhibitor) to Osteoarthritis
One-Sentence Summary
Vaborbactam is a serine β-lactamase inhibitor (boronic acid ester structure) that inhibits KPC-type carbapenemases; it is not currently authorized as a standalone product in the EU and no original approved indication is recorded in this Evidence Pack. The TxGNN model predicts it may be effective for Osteoarthritis, but this prediction is supported by 0 clinical trials and 0 publications, and the evidence pack itself flags the score as a possible artifact of sparse-node inference in the knowledge graph.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication text on record (drug not authorized in the EU market; DrugBank original indications list is empty) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.52% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Vaborbactam is marked as unavailable in this Evidence Pack. Based on the limited information available, Vaborbactam is a serine β-lactamase inhibitor that works by inhibiting KPC-type carbapenemases, and is typically used as an adjuvant combined with a carbapenem antibiotic to restore antibacterial activity against carbapenem-resistant organisms. No original indication has been formally recorded for this candidate, so its proven efficacy profile cannot be assessed from this pack.
There is no established pharmacological or clinical link between β-lactamase inhibition and osteoarthritis pathology, which involves cartilage degradation and joint inflammation through entirely different biological pathways (e.g., matrix metalloproteinase activity, cytokine-driven synovitis). The evidence pack’s own rationale explicitly notes that Vaborbactam has “no known anti-inflammatory, chondroprotective, or joint-related biological mechanism,” and suggests the high TxGNN score may reflect an inference bias arising from sparse graph connectivity around this drug node rather than genuine biological plausibility.
Given the absence of any mechanistic rationale, clinical trial evidence, or literature support, this prediction should be treated as a low-confidence, model-only signal rather than a credible repurposing candidate at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by an AI model score (L5) with zero clinical trials or literature, no plausible mechanistic link between β-lactamase inhibition and osteoarthritis pathology, and the evidence pack itself flags the score as a likely sparse-node inference artifact. Combined with a Blocking data gap on safety labeling (TFDA/EMA warnings and contraindications) and a High-severity gap on mechanism of action, this candidate does not meet the bar to advance past initial screening.
To proceed, the following is needed:
- Official safety labeling data (SmPC/package insert warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action from DrugBank or primary literature — currently a High-severity data gap
- Confirmation of the drug’s original approved indication(s), since none are currently on record
- Independent biological plausibility review before allocating resources to preclinical or clinical validation for osteoarthritis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.